RTTNews | Jul 23, 2020 09:20AM EDT

09:20 Thursday, July 23, 2020 (RTTNews.com) - CymaBay Therapeutics Inc. (CBAY) said that the U.S. Food and Drug Administration lifted clinical holds on seladelpar for all three Investigational New Drug (IND) Applications in Nonalcoholic Steatohepatitis or NASH, Primary Biliary Cholangitis or PBC and Primary Sclerosing Cholangitis or PSC.

In Thursday pre-market trade, CBAY was trading at $4.58, up $1.07 or 30.48%.

In November 2019, CymaBay halted all clinical trials of seladelpar after atypical histologic findings with no clinical or laboratory correlates were identified at the planned end-of treatment biopsy review of a 52-week Phase 2 NASH study. The FDA concurred with this decision and placed all active INDs for seladelpar on clinical hold.

The company said the expert panel found no clinical, biochemical or histological evidence of seladelpar-related liver injury in the Phase 2 NASH study and unanimously supported re-initiating clinical development of seladelpar pending approval by the FDA.

Based on the results of investigation and expert panel conclusions, FDA concluded that clinical trials for NASH, PBC and PSC may resume.

Read the original article on RTTNews ( https://www.rttnews.com/3113752/cymabay-says-clinical-hold-lifted-on-seladelpar-inds-in-nash-pbc-and-psc-stock-up.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved